Catalent Pharma Solutions’ Post

Great to speak with Pharma's Almanac and share my thoughts on current investment trends. Read more below! #investment #biotech #pharma #cgt #cellandgenetherapy #celltherapy #atmps #future #vision #thoughts #development NextCell Pharma AB

N4 Pharma has been featured in a new industry roundtable by Pharma's Almanac to identify the current investment trends in the pharmaceutical industry and propose how they are influencing the direction of the #pharma sector. Our CEO Nigel Theobald discusses why investment into innovative technologies, such as Nuvec®, is needed to support the delivery of new and emerging therapies without the drawbacks of current lipid-based delivery systems. Read our response here: https://lnkd.in/g3C3Dj7B

[Latest] Global Biotechnology Industry Outlook - 2024  Download PDF Brochure: https://lnkd.in/duvYqaKJ The report "The Global #Biotechnology #Industry Outlook 2024", despite the economic uncertainties and post-COVID slump in recent times, biotech companies have demonstrated adaptability throughout 2023. Overall, the market within the biotech sector expanded by 10-15% during this period. Ongoing innovation, mergers, and acquisitions (M&A), approval, and marketing of new products and medications contribute to the sustained growth of the market. Some of the key developments witnessed by the biotech industry in 2023: - The approval of innovative therapies such as CRISPR-Cas9, allogeneic cell therapy, and microbiome-based drugs represents a groundbreaking era in medical science. - The Modernization Act 2.0 marks a significant departure from the previous regulatory landscape by eliminating the federal mandate requiring experimental drugs to undergo testing on animals before advancing to human clinical trials. - The trend of increasing collaboration with biotech companies signifies a strategic move towards therapeutic advancement in the healthcare industry. For instance, in October 2023, Antiverse and GlobalBio, Inc. extended collaboration to progress the development of antibody-based cancer therapeutics. Key Market Players Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), BD and Company (US), GE HealthCare (US), Agilent Technologies, Inc. (US), Merck Group KGAA (Germany), Inc (US), QIAGEN (Germany), Illumina (US). F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Novartis (Switzerland), Merck Group & Co. (US), Sanofi (France), Amgen (US), Gilead Sciences (US), Biogen (US), Bristol Myers Squibb (US) and GSK (UK)

Thoughts on this? >> Galapagos enters deal to boost CAR-T therapy production - Pharmaceutical Technology >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharmaceutical #pharma #competitivemarketing

@Flagship Pioneering has unveiled @Abiologics, a groundbreaking company set to revolutionize biologics with a new class of supranatural and programmable medicines called Synteins™. Key highlights: --Synteins are computationally designed using AI and synthesized with novel building blocks --$50 million initial commitment from Flagship Pioneering --Potential for less frequent dosing, oral delivery, and expanded therapeutic reach --Initial focus on oncology and immunology indications Abiologics' platform integrates cutting-edge generative AI, automated polymer synthesis, and chemical functionalization to create biologics that surpass the limitations of nature. By using artificial building blocks beyond the 20 natural amino acids, Synteins can evade the immune system and potentially access previously unreachable parts of the body. Novartis Genentech Amgen Roche Biogen Regeneron Moderna #Biotechnology #ArtificialIntelligence #DrugDiscovery #Biotherapeutics #Innovation #PharmaTech Read the full story here:

From changing business models to AI and a digital-first approach, we're sharing the top 10 most impactful trends that continue to shape the pharmaceutical industry this year. Read the full list: https://lnkd.in/earXdAdk #trends #2024trends #whitepaper #pharma #lifesciences

Isomorphic Labs, a London-based AI drug discovery startup, has partnered with Eli Lilly & Co. and Novartis AG, two of the world's largest pharmaceutical companies, in deals valued at nearly $3 billion. Isomorphic Labs will utilize AlphaFold, an AI system developed by DeepMind, to predict protein structures and focus on small molecule therapeutics. The partnerships with Eli Lilly and Novartis provide Isomorphic Labs with significant financial resources, industry expertise, and market validation, accelerating their efforts in developing innovative drugs and bringing them to patients faster. Takeaway: The collaboration between Isomorphic Labs, Eli Lilly, and Novartis signifies a powerful combination of AI-driven drug discovery, financial backing, and industry expertise, which will accelerate the development of life-saving small molecule therapeutics. #AI #DrugDiscovery #Pharmaceuticals #ArtificialIntelligence #DeepLearning #AlphaFold #IsomorphicLabs #EliLilly #Novartis #Innovation

Thoughts on this? >> Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results - Yahoo Finance >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #healthcare #pharma #pharmaceutical #biotech

Thoughts on this? >> Galapagos enters deal to boost CAR-T therapy production - Pharmaceutical Technology >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #competitivemarketing #healthcare #biotech

Thoughts on this? >> Nona Biosciences partners with Alaya.bio for CAR-T therapy - Pharmaceutical Technology >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #pharma #biotech #competitivemarketing